# WISCONSIN ALUMNI RESEARCH FOUNDATION

POST OFFICE BOX 2037 • PHONE 257-4851 (AREA CODE 608) • 506 N. WALNUT ST.

MADISON, WIS. 53701

April 7, 1970

Professor William H. Young Assistant to the President University of Wisconsin 210 North Hall Madison, Wisconsin 53706

Dear Bill:

During our meeting with Ward we had promised to send you a summary of the determinations which we have received from the Department of Health, Education, and Welfare and a summary of our obligations under those determinations as well as a report relating to matters which the Foundation is handling under the Institutional Agreement. We also agreed to include a statement as to which obligations had been satisfied and give you some idea of our procedure for flagging the various deadlines which we must meet. You will find enclosed such a summary which we will update from time to time as the situation requires.

Rest regards.

Very truly yours,

Howard W. Bremer Patent Counsel

HWB:rw Enc.

cc--Messrs. Rosten; Woerpel; Abrams

# WARF'S OBLIGATIONS TO THE DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE (DHEW)

#### I. Determinations under Section 8.2(b)

A. Green-Crane-Lester - Coenzyme Q U.S. Patent No. 3, 162, 654, issued December 22, 1964 Determination - December 16, 1959

In accordance with Section 6 of the determination, U.S. Patent No. 3,162,654 was assigned to the U.S. Government, January 22, 1965.

WARF retained foreign rights and foreign patents were maintained by Merck & Co., Inc. through 1969, after which time they were allowed to lapse by nonpayment of tax by mutual agreement between Merck and WARF. The Canadian patent will remain in force until August 16, 1983, as there is no tax on Canadian patents.

B. Sih - Process for Preparing Steroids

U.S. Patent No. 3,507,749, issues April 21, 1970

Determination - Foreign - October 22, 1965

December 15, 1965

U.S. - July 11, 1967

## 1. Obligations complied with:

- a. Copy of recorded assignment of U.S. patent application was sent to DHEW on November 21, 1967.
- b. License to Government on U.S. patent application was executed on October 23, 1967.
- c. Licenses to Government on each foreign patent application were executed on March 10, 1967.

## 2. Obligations outstanding:

a. Provide written annual reports commencing one year from the date of the determination agreement regarding the development and commercial use of the invention. The report for this invention is due annually by July 11.

- b. Within three years from the date patent issues WARF must show cause why it should retain all right, title and interest in the invention. Deadline is April 21, 1973.
- c. All licenses shall be subject to the conditions of the determination and copies of all licenses shall promptly be furnished to DHEW.
- 3. Obligation obsolete because of issuance of patent:
  - a. If WARF plans to abandon U.S. patent application it must offer to transfer rights to DHEW. If assignment is not requested within 90 days of receipt of offer, WARF may abandon patent application.
- C. DeLuca-Blunt 25-Hydroxycholecalciferol
  U.S. Patent Application Serial No. 741, 239, filed July 1, 1968
  Determination December 5, 1969
  - 1. Obligations outstanding:
    - a. Furnish copy of recorded assignment of U.S. patent application to DHEW.
    - b. Grant license to Government on U.S. patent application.
    - c. Grant licenses to Government on each foreign patent application.
    - d. Provide written annual reports commencing one year from the date of the determination agreement regarding the development and commercial use of the invention. The report for this invention is due annually by December 5.
    - e. Within three years from the date patent issues WARF must show cause why it should retain all right, title and interest in the invention.
    - f. All licenses shall be subject to the conditions of the determination and copies of licenses shall promptly be furnished to DHEW.
    - g. If WARF plans to abandon U.S. patent application it must offer to transfer rights to DHEW. If assignment is not requested within 45 days of receipt of offer, WARF may abandon patent application.

D. Newhall - Internal Combustion Engine and Combustion Process
U.S. Patent Application Serial No. 15,345, filed March 2, 1970

A determination under Section 8.2(b) was requested from DHEW on February 27, 1970. To date we have had no reply.

- II. Determination under Section 8.2(d)
  - A. West-Tobey Cyclopropene Derivatives
    U.S. Patent No. 3,335,194, issued August 8, 1967
    Determination April 29, 1966
    - 1. Obligations complied with:
      - a. Copy of patent application and filing information was furnished to DHEW on November 10, 1965 and June 1, 1966.
      - b. License to Government on U.S. patent application was executed on February 2, 1967.
    - 2. Obligations outstanding:

None

- III. Institutional Agreement
  - A. Summary of WARF's obligations to the Department of Health, Education, and Welfare (DHEW)

A written report must be submitted to DHEW annually by September 30 reporting on inventions falling within the scope of the Institutional Agreement for the period July 1 thru June 30. In order that no inventions are omitted a separate list is kept for each reporting period. Also, a record is kept of the date each report is submitted and a copy of the report is attached to this record.

The attached invention record form has been prepared for complying with WARF's other obligations under the Institutional Agreement.

- B. To date WARF has received two inventions under the Institutional Agreement.
  - 1. Sih Process for Preparing L-dopa (thru microbiological means)
    U.S. Patent Application Serial No. 862,061, filed September 29, 1969.

A copy of the U.S. patent application, which was also considered to be the written invention report, was sent to DHEW September 25, 1969. The Serial No. and filing date was sent January 8, 1970. A copy of the recorded assignment was sent February 26, 1970. A license to the U.S. Government under the U.S. patent application was executed January 13, 1970.

The next pertinent date for this invention is the foreign filing deadline which is September 29, 1970.

2. Perrin - Method for Reducing Drug Availability in Combination with Highly Protein Bound Salts

A written invention report was sent to DHEW August 8, 1969.

A publication appeared in the Journal of Pharmaceutical Science, December 1969. The date of statutory bar to U.S. filing is November 30, 1970. If WARF decides not to file a U.S. patent application on this invention, it must notify DHEW 90 days prior to the statutory bar, or by August 30, 1970.

In order to assure complying with WARF's obligations set forth in the determinations from DHEW and the Institutional Agreement, all pertinent deadlines are recorded on the calendar for call-up and copies of the monthly calendar are sent to Messrs. Abrams, Bremer, and Woerpel in advance of the deadlines. They also receive memos reminding them of each due date a month or two in advance of the deadline.

INSTITUTIONAL PATENT AGREEMENT GOVERNING GRANTS AND AWARDS FROM THE DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

This AGREEMENT made and entered into this	day of
, 19, by and between th	e United
States of America as represented by the Assistant S	ecretary
(Health and Scientific Affairs) of the Department of	f Health,
Education, and Welfare, hereinafter sometimes refer	red to as
the Grantor, and The University of Miscourse	
(fistitution)	

hereinafter referred to as the Grantee.

#### WITNESSETH

WHEREAS, the Regulations of the Department of Health, Education, and Welfare, covering inventions resulting from research grants, fellowship awards, and contracts for research (45 CFR parts 6 and 8), provide in Secs. 8.1 through 8.5 that upon approval by the Assistant Secretary (Health and Scientific Affairs) the ownership and disposition of domestic and foreign rights to inventions arising out of activities assisted by grants and awards may be left to the Grantee pursuant to its approved established patent policy, with such modifications as may be agreed upon; and

WHEREAS, the Grantee is desirous of entering into an agreement whereby it has a first option to retain principal rights in and to administer inventions made in the course of or under research supported by grants and awards from the Department of Health, Education, and Welfare, pursuant to the aforesaid Regulations; and

WHEREAS, the Assistant Secretary (Health and Scientific Affairs) has reviewed the patent policy of the Grantee as set forth in the University letters dated April 19, 1967 and Internet Scientific and its practices thereunder and has found them to be acceptable, subject to the provisions of this Agreement, and that said policy for administration by the Grantee of patents in the public interest and are consistent with the stated objectives of

and the enclosures thereto

the President's Statement and Memorandum of Government Patent Policy, issued October 10, 1963; and

NOW, THEREFORE, in consideration of the foregoing, the parties hereto agree as follows:

#### I. Scope of Agreement

This Agreement shall define the rights of the parties hereto regarding disposition of title to inventions made in the course of or under research supported by grants and awards from the Department of Health, Education, and Welfare, which are subject to the Department Patent Regulations and are issued after the date hereof.

#### II. Definitions

- (a) The term "subject invention" as used in this Agreement means any process, machine, manufacture, composition of matter or design, or any new or useful improvement thereof, and any variety of plant which is or may be patentable under the Patent Laws of the United States made in the course of or under research supported by grants and awards from the Department of Health, Education, and Welfare.
- (b) The term "made" when used in relation to any invention or discovery means its conception or first actual reduction to practice.

## III. Disposition of Principal Rights to Subject Inventions

The Grantee shall have the right to elect to file patent application in the United States and in foreign countries on any subject invention and to administer such invention pursuant to the provisions of this Agreement. Grantee shall notify Grantor at the time each subject invention is reported to Grantor as required by paragraph V hereof, if it intends to file patent application(s) on and to administer the invention. If Grantee does not elect to file a U. S. patent application on and to administer a subject invention, it shall notify Grantor in sufficient time to permit Grantor to file a U.S. patent application thereon. In such event, all rights in and to such invention, except rights in any foreign patent application filed by Grantee, shall be subject to disposition by the Grantor in accordance with its Regulations then in effect.

#### IV. Supplementary Patent Agreements

invention.

- (a) The Grantee shall obtain patent agreements from all persons who perform any part of the work under a grant or award from the Department of Health, Education, and Welfare, exclusive of clerical and manual labor personnel, requiring that such persons promptly report and assign all subject inventions to Grantee or its approved patent management organization.
- (b) The Grantee shall include the following provision in any contract it enters into involving research and/or development for which DHEW research grant or award funds are utilized.

"The Contractor hereby agrees to report fully and
promptly to
(Grantee)
any invention conceived or first actually reduced to practice in performance of this contract
(hereinafter referred to as "such invention(s)",
and to assign all right, title and interest in and to such invention to
(Grantee)
or its designee.
"In addition, the Contractor agrees to furnish the following materials, disclosures and reports:
"(i) Upon request, such duly executed instruments (Prepared by the
(Grantee)
or its designee) and such other papers as are
deemed necessary to vest in the
or its
(Grantee)
designee the rights granted under this clause and to enable the
(Grantee)
or its designee to apply for and prosecute any patent application, in any country, covering such

- "(ii) Interim reports on the first anniversary of this contract where extended or renewed and every year thereafter listing all such inventions made during the period whether or not previously reported or certifying that no inventions were conceived or first actually reduced to practice during the applicable period.
- "(iii) Prior to final settlement of this contract, a final report listing all such inventions including all those previously listed in interim reports, or certifying that no inventions were conceived or first actually reduced to practice under the contract."

#### V. Report of Invention

- (a) The Grantee shall submit a written invention report to the Grantor of each subject invention promptly after conception or first actual reduction to practice.
- (b) Such invention report shall be furnished directly to the Grantor in addition to any other requirement under any grant or award for the submission of progress or financial reports, and whether or not reference to subject invention has been made in any progress or other report furnished to the Grantor; such report shall include description of such invention, appropriately illustrated by a simple sketch or diagram, to permit the invention to be understood and evaluated, and such other information as Grantor may require.
- (c) The report shall specify whether or not Grantee intends to file a U.S. patent application or any foreign patent application on the invention. Notice of an election not to file a U.S. patent application shall be given Grantor not less than ninety (90) days prior to the date a statutory bar becomes effective.
- (d) If the Grantee specifies that no U.S. patent application will be filed (or having specified that it intends to file, thereafter notifies the Grantor to the contrary), the Grantee shall promptly inform the Grantor of the date and identification of any known publication of

subject invention made by or known to the Grantee or, where applicable, of any contemplated publication to be made by or known to the Grantee, and also the date subject invention or any embodiment thereof was first in public use or on sale in the United States and shall furnish such other information (and have executed such documents as provided in VIII(f) as may be required to enable the Grantor to make disposition of subject invention rights).

# VI. Administration of Inventions on Which the Grantee Elects to File Patent Applications

- (a) The Grantee shall require assignment to it of all right, title and interest in and to each subject invention on which it elects to file any patent application for administration by it in accordance with and subject to the terms and conditions herein set forth. Assignments from the inventor to the Grantee under U.S. patent applications shall be promptly obtained and recorded by the Grantee in the United States Patent Office and copies of the recorded assignment shall be furnished to the Grantor.
- (b) The Grantee shall grant to the Government of the United States a nonexclusive, irrevocable, royalty-free license for governmental purposes and on behalf of any foreign government, pursuant to any existing or future treaty or agreement with the United States under each U.S. or foreign patent application it elects to file on a subject invention. The form of the license to be granted shall be as set forth in Exhibit "A", attached hereto, and by this reference made a part hereof. Any license issued by Grantee shall be made expressly subject to the license to the Government of the United States.
- (c) The Grantee shall administer those subject inventions to which it elects to retain title in the public interest and shall, except as provided in paragraph (d) below, make them available through licensing on a nonexclusive, royalty-free or reasonable royalty basis to qualified applicants.
- (d) The Grantee may license a subject invention on an exclusive basis if it determines that nonexclusive licensing will not be effective in bringing such inventions to the commercial market in a satisfactory manner. Exclusive licenses

should be issued only after reasonable efforts have been made to license on a nonexclusive basis, or where the grantee has determined that an exclusive license is necessary as an incentive for development of the invention or where market conditions are such as to require licensing on an exclusive basis. Any exclusive license issued by Grantee under a U.S. patent or patent application shall be for a limited period of time and such period shall not, unless otherwise approved by the Assistant Secretary (Health and Scientific Affairs), exceed three years from the date of the first commercial sale in the United States of America of a product or process embodying the invention, or eight years from the date of the exclusive license, whichever occurs first, provided that the licensee shall use all reasonable effort to effect introduction into the commercial market as soon as practicable, consistent with sound and reasonable business practices and judgment. Any extension of the maximum period of exclusivity shall be subject to approval of the Grantor. Upon expiration of the period of exclusivity or any extension thereof, licenses shall be offered to all qualified applicants at a reasonable royalty rate not in excess of the exclusive license royalty rate.

- (e) Any license granted by the Grantee to other than the Government of the United States under any patent application or patent on a subject invention shall include adequate safeguards against unreasonable royalty and repressive practices. Royalties shall not, in any event, be in excess of normal trade practice? Such license shall also provide that all sales to the U.S. Government shall be royalty free.
- (f) If permitted by its patent policies and the terms of the grant or award under which an invention is made, the Grantee may share royalties received with the inventor(s), provided that the Grantee shall not pay the inventor(s) more than (1) fifty percent (50%) of the first \$3,000 gross royalty paid under the patent, (2) twenty-five percent (25%) of the gross royalty income between \$3,000 and \$13,000, and (3) fifteen percent (15%) of the gross royalty in excess of \$13,000. The balance of the royalty income after payment of expenses incident to the administration of all inventions assigned to it pursuant to the provisions of this Agreement shall be utilized for the support of educational and research pursuits.

(g) All licenses issued by the Grantee to other than the Government of the United States under any patent application or patent on a subject invention shall be subject to the conditions of this Agreement and shall specifically reserve to Grantor those rights specified in paragraph XII hereof. The Grantee shall, upon request, promptly furnish copies of any license agreements entered into by it to the Department.

#### VII. Patent Management Organizations

The Grantee shall not assign any subject invention to parties other than the Grantor in circumstances as set forth in this agreement except it may assign rights in the invention to a nonprofit patent management organization, provided that the patent administration agreement between such organization and Grantee is approved by the Grantor. Any reference to a Grantee in this Agreement shall also include a patent management organization when applicable and an assignment to such an organization shall be subject to all the terms and conditions of this Agreement.

#### VIII. Patent Applications

- (a) Grantee shall promptly furnish Grantor with a copy of each U.S. patent application filed in accordance with this Agreement specifying the filing date and the serial number. Grantee shall promptly notify Grantor of each foreign patent application filed, including filing date and serial number, and shall furnish a copy of each application upon request.
- (b) Upon request, Grantee shall fully advise the Grantor concerning all steps and actions taken during the prosecution of any patent application covering a subject invention and shall, upon request, furnish copies of any final actions, amendments, petitions, motions, appeals, or other papers relating to the prosecution of said application.
- (c) Upon request, the Grantee shall promptly furnish to the Grantor an irrevocable power of attorney granting the right to inspect and make copies of any patent application covering a subject invention or any of the final actions, amendments, petitions, motions, appeals, or other papers relating to the prosecution of said application.

(d) The Grantee shall include the following statement in the first paragraph of the specification following the abstract of any patent application filed on a subject invention:

"The invention described herein was made in the course of work under a grant or award from the Department of Health, Education, and Welfare."

- (e) The Grantee shall not abandon any U.S. patent application filed on a subject invention without first offering to transfer all rights in and to such application to the Grantor not less than forty-five (45) days prior to the date a reply to the Patent Office action is due. If the Grantor does not request assignment within thirty (30) days of receipt of this offer, the Grantee may permit the application to go abandoned.
- (f) If the Grantee elects to file no patent application or to abandon prosecution of a U.S. patent application on a subject invention, he shall, upon request, execute instruments or require the execution of instruments (prepared by the Grantor) and such other papers as are deemed necessary to vest in the Grantor all right, title and interest in the subject invention to enable the Grantor to apply for and prosecute patent applications in any country.

## IX. Invention Reports and Certifications

Notwithstanding the provisions of this Agreement, the Grantee shall provide invention reports and certifications as may be required by the terms of any grant or award.

#### X. Disclosure and Publication

The Grantee shall not bar or prohibit publication of disclosures of inventions on which patent applications have been filed.

The Grantor shall have the right to publish and make disclosure of any information relating to any subject invention whenever deemed to be in the public interest, provided that upon request reasonable opportunity shall be afforded the Grantee to file U.S. and foreign patent applications.

#### XI. Reports on Development and Commercial Use

The Grantee shall provide a written annual report to the Department on or before September 30 of each year covering the preceding year, ending June 30, regarding the development and commercial use that is being made or intended to be made of all subject inventions left for administration by the Grantee. Such reports shall include information regarding development, the date of first commercial sale, gross sales by licensees, gross royalties received by the Grantee, and such other data and information as the Department may specify.

#### XII. Additional Licenses

- (a) The Grantee agrees that if it, or its licensee, has not taken effective steps within three years after a United States patent issues on a subject invention left for administration to the Grantee to bring that invention to the point of practical application, and has not made such invention available for licensing royalty-free or on terms that are reasonable in the circumstances, and cannot show cause why he should retain all right, title and interest for a further period of time, the Grantor shall have the right to require (1) assignment of said patent to the United States, as represented by the Grantor; (2) cancellation of any outstanding exclusive licenses under said patent; or (3) the granting of licenses under said patent to an applicant on a nonexclusive, royalty-free basis or on terms that are reasonable in the circumstances.
- (b) The Grantor reserves the right to license or to require the licensing of other persons under any U.S. patent or U.S. patent application filed by the Grantee on a subject invention on a royalty-free basis or on terms that are reasonable in the circumstances, upon a determination by the Assistant Secretary (Health and Scientific Affairs) that the invention is required for public use by governmental regulations, that the public health, safety, or welfare requires the issuance of such licenses), or that the public interest would otherwise suffer unless such license(s) were granted. The Grantee and its licensees shall be given written notice of any proposed determination pursuant to this subparagraph not less than thirty (30) days prior to

the effective date of such determination, and that if requested, shall be granted a hearing before the determination is issued and otherwise made effective.

## XIII. Inventions by Federal Employees

Notwithstanding any provision contained in this Agreement, inventions made by Federal employees, or by Federal employees jointly with others, shall be subject to disposition under provisions of Executive Orders, Governmental and Department Regulations applicable to Federal employees.

#### XIV. Termination

This Agreement may be terminated by either party for convenience upon thirty (30) days written notice. Disposition of rights in, and administration of inventions made under grants or awards entered into during and subject to this Agreement will not be affected by such a termination except that in the event the Department terminates this Agreement because of a failure or refusal by Grantee to comply with its obligations under Articles V or VI of this Agreement, the Department shall have the right to require that the Grantee's entire right, title and interest in and to the particular invention with respect to which the breach occurred be assigned to the United States of America, as represented by the Secretary of the Department of Health, Education, and Welfare.

#### XV. Limitation

It is agreed and understood that this Agreement shall not apply to any grants or awards issued under statutes containing requirements for disposition of invention rights with which the provisions of this Agreement are inconsistent. It is further agreed that any constituent agency of the Department of Health, Education, and Welfare may, with the approval of the Assistant Secretary (Health and Scientific Affairs), provide as a condition of any grant or award that this Agreement shall not apply thereto. It is also agreed that any constituent agency of the Department of Health, Education, and Welfare may provide, subject to approval by the Assistant Secretary (Health and Scientific Affairs), that this Agreement shall apply to specific research contracts.

#### LICENSE TO THE UNITED STATES GOVERNMENT

WHEREAS,	es con the control of the control of
	(Inventor) , has invented
	and filed a patent
(Invention) application thereon in	
	(Country)
bearing Serial No.	, filing date;
and	
	as made in the course of research om the Department of Health, Education
	es Government is entitled to certain vention and application by reason of s); and
	(Institution)
	Licensor" has acquired by assignment tire right, title, and interest of ention;

#### NOW. THEREFORE:

The Licensor, in consideration of the premises and other 1. good and valuable consideration, hereby grants and conveys to the United States Government a royalty-free, nonexclusive and irrevocable license for governmental purposes and on behalf of any foreign government pursuant to any existing or future treaty or agreement with the United States under the aforesaid patent application and any and all divisions or continuations, and in any and all patents or reissues which may be granted thereon during the full term or terms thereof. As used herein, "governmental purpose" means the right of the Government of the United States (including any agency thereof, state or domestic municipal government) to practice and have practiced (made or have made, used or have used, sold or have sold) throughout the world by or on behalf of the Government of the United States.

- 2. The Licensor covenants and warrants that he has the right to grant the foregoing license, and that any assignment which he may make of the invention or the said patent applications or patents thereon, shall expressly be made subject to this license.
- 3. The Licensor agrees that the Government shall not be estopped at any time to contest the enforceability, validity, scope of, or title to, any patent or patent application herein licensed.

에 보는 기업으로 지원하고 있다면 함께 보고 있다. 현실 	
	(Institution)
	(Signature)
	(Print or type name)
Date	(Official Title)

#### CERTIFICATE

				Corryr)	t
that I am the of the Institution	named as	Licensor	herein;	that signed this	- S
License on behalf of said Institution for and in behalf governing body, as powers.	on; and the	r salu b. esitutio	n by aut	- · · · · · · · · · · · · · · · · · · ·	

# REQUESTS FOR DHEW INSTITUTIONAL PATENT AGREEMENTS

Requests for DHEW Institutional Patent Agreements should be addressed to the Assistant Secretary (Health and Scientific Affairs) and should provide sufficient information to enable a thorough evaluation of the grantee's established policies and procedures for the administration of inventions arising out of research conducted at the institution. Such requests should generally include the following information:

- 1. A copy of the institution's formal patent policy.
- Name and title of institutional official responsible for administration of patent and invention matters.
- 3. A description of the institution's procedures for identifying and reporting inventions and for filing patent applications.
- 4. A copy of the form of agreement required to be signed by faculty and other employees of the institution engaged in research.
- 5. A copy of the invention report form or outline utilized for preparation of invention reports at the institution.
  - 6. Advice as to whether the institution has a formal agreement with any nonprofit patent management organizations, such as Research Corporation, Battelle Development tions, such as Research Corporation, Battelle Development Corporation, and other similar organizations. Copies of any agreements in effect should be enclosed.
  - 7. A general description of the institution's past patent licensing activities, including the following:
    - a) Number of patents obtained during the past ten years;
    - b) Number of exclusive licenses issued;
    - c) Number of nonexclusive licenses issued; <
    - d) Estimated gross royalty income over past ten years;
    - e) A general description of royalties charged, including minimum and maximum royalty rates.

mar john